Diplomat Launches Pharmacy Tech Certification Program
FLINT, Mich. – March 3, 2016 – The nation’s largest independent specialty pharmacy expands its technician training program after receiving approval by the Michigan Board of Pharmacy.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it has been approved by the Michigan Board of Pharmacy to facilitate an employer-based pharmacy technician training program with examinations on-site.
To learn more about Diplomat and the courses it offers, click here.
This training program is exclusively for Diplomat employees. Although Diplomat has had a pharmacy technician training program in place since 2011, this board-approved program further strengthens Diplomat’s commitment to supporting employees with achieving higher levels of education. Employees who successfully complete the employer-based pharmacy technician program and examination may be considered for state licensure.
Pharmacy technician licensure is a requirement for individuals in Michigan interested in pursuing a career in pharmacy, specifically for those who perform certain functions to support a licensed pharmacist. According to the United States Bureau of Labor Statistics, the need for employing pharmacy technicians is expected to grow 9 percent nationally through 2024.
“The need for licensed pharmacy technicians is growing tremendously in Michigan,” said Stephanie LaPointe, Pharm.D., manager of education and training at Diplomat. “Having a program at Diplomat that focuses on specialty pharmacy helps to ensure that the individuals serving in technician roles are appropriately supporting the specialty patient experience. Through this training program, Diplomat will continue to support its pharmacy staff professionally and provide the best customer care to our patients by becoming experts in their field.”
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | firstname.lastname@example.org
Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education, and Human Resources
810.768.9863 | email@example.com
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV4 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.2 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago